NCT07597772RecruitingEarly phase 1
Preliminary Trial of SNA014 for Pancreatic Cancer
A Clinical Study on the Use of ⁶⁸Ga-labelled Claudin 18.2 as a Contrast Agent in Combination With PET/CT for the Imaging of Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 19 May 2026
Brief summary (registry, in English)
68Ga labeled Claudin 18.2 contrast agent combined with PET/CT for pancreatic cancer
- Status (registry)
- Recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- First submitted
- 21 Apr 2026
- Start date
- 1 Oct 2025
- Primary completion date
- 1 Jul 2026
- Lead sponsor
- SmartNuclide Biopharma
- Diseases
- Pancreatic cancer
- NCT number
- NCT07597772
What you commit to
- Study type: Interventional · Early phase 1
- Planned participants: 12
- From 1 Oct 2025 to the primary completion date, 1 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with other clearly diagnosed malignant tumours;
- Patients with uncontrolled severe infections, or those with other serious comorbidities;
Other
- Patients with a life expectancy of ≤3 months;
- Pregnant or breastfeeding patients, and patients of childbearing potential who refuse to use appropriate contraception during the trial;
- Patients deemed unsuitable for participation in this study by the investigator.
Who the study is looking for
- Aged between 18 and 75 years (inclusive);
- Possessing legal capacity, voluntarily participating in this clinical trial, and having signed the informed consent form (ICF);
- Patients with a confirmed diagnosis of pancreatic cancer whose tumours are suitable for Claudin-18.2 testing;
- Results of gastroscopy, CT, MRI or PET-CT scans performed within the past month (if available);
- Pathology test results from within the past year;
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tianjin Medical University Cancer Institute and Hospital Coordinator of this site? Confirm its status | Tianjin | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.